Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genmab Earns $10M Janssen Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Genmab Earns $10M Janssen Milestone

Daratumumab Phase III multiple myeloma trial advances

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab A/S has reached the fourth milestone in its daratumumab collaboration with Janssen Biotech, triggering a $10 million payment related to progress in the ongoing Phase III study (“CASTOR” MMY3004).
 
The Phase III study is evaluating daratumumab in combination with bortezomib and dexamethasone compared to bortezomib and dexamethasone alone for the treatment of relapsed or refractory multiple myeloma. The primary endpoint of the study is progression free survival (PFS).
 
“We are very pleased with the firm progress being made in the daratumumab development program under the direction of our strategic partner Janssen. At Genmab we are committed to developing differentiated therapeutics to fight cancer, and it is therefore rewarding to see one of our antibodies moving rapidly through clinical development,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics